Shaz Beth H, Dente Christopher J, Harris Robert S, MacLeod Jana B, Hillyer Christopher D
Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia, USA.
Anesth Analg. 2009 Jun;108(6):1760-8. doi: 10.1213/ane.0b013e3181a0b6c6.
The management of massively transfused trauma patients has improved with a better understanding of trauma-induced coagulopathy, the limitations of crystalloid infusion, and the implementation of massive transfusion protocols (MTPs), which encompass transfusion management and other patient care needs to mitigate the "lethal triad" of acidosis, hypothermia, and coagulopathy. MTPs are currently changing in the United States and worldwide because of recent data showing that earlier and more aggressive transfusion intervention and resuscitation with blood components that approximate whole blood significantly decrease mortality. In this context, MTPs are a key element of "damage control resuscitation," which is defined as the systematic approach to major trauma that addresses the lethal triad mentioned above. MTPs using adequate volumes of plasma, and thus coagulation factors, improve patient outcome. The ideal amounts of plasma, platelet, cryoprecipitate and other coagulation factors given in MTPs in relationship to the red blood cell transfusion volume are not known precisely, but until prospective, randomized, clinical trials are performed and more clinical data are obtained, current data support a target ratio of plasma:red blood cell:platelet transfusions of 1:1:1. Future prospective clinical trials will allow continued improvement in MTPs and thus in the overall management of patients with trauma.
随着对创伤性凝血病、晶体液输注的局限性以及大量输血方案(MTPs)的实施有了更深入的了解,大量输血创伤患者的管理得到了改善。MTPs涵盖输血管理和其他患者护理需求,以减轻酸中毒、体温过低和凝血病这一“致命三联征”。由于最近的数据表明,更早、更积极地进行输血干预以及使用接近全血的血液成分进行复苏可显著降低死亡率,目前美国和全球范围内的MTPs正在发生变化。在此背景下,MTPs是“损伤控制复苏”的关键要素,“损伤控制复苏”被定义为应对上述致命三联征的主要创伤的系统方法。使用足够量血浆以及凝血因子的MTPs可改善患者预后。MTPs中与红细胞输注量相关的血浆、血小板、冷沉淀和其他凝血因子的理想用量尚不清楚,但在进行前瞻性、随机临床试验并获得更多临床数据之前,目前的数据支持血浆:红细胞:血小板输注的目标比例为1:1:1。未来的前瞻性临床试验将使MTPs以及创伤患者的整体管理持续得到改善。